I’ve spent 11 years sitting in back-office conference rooms, managing speaker schedules, wrestling with AV requirements, and obsessively color-coding my master spreadsheet. I have seen the same abstract presented three different ways at three different meetings, and I have heard more "groundbreaking" claims than I care to count. When I look at an annual meeting agenda, my first thought isn't "Wow, look at all these headlines." It is: "What will you actually do differently on Monday morning when you get back to the clinic?"
If you are heading to the American Society of Clinical Oncology (ASCO) Annual Meeting, you are going to be bombarded with data. But data is not the same thing as practice-changing evidence. To help you filter the signal from the noise, let’s look at the core pillars of the ASCO program and how they fit into your actual clinical workflow.
The Clinical Core: Understanding the ASCO Mission
Before we dive into the specific topics, we need to distinguish between the big players. The American Society of Clinical Oncology (ASCO) is the industry standard for clinical practice updates. Unlike the American Association for Cancer Research (AACR), which leans heavily into bench-to-bedside discovery and preclinical mechanisms, ASCO is where the "Monday morning" decisions are made. Furthermore, if you are wondering how these trials eventually impact your patient care, always keep an eye on how these abstracts align with the NCCN (National Comprehensive Cancer Network) clinical practice guidelines. If a study presented at ASCO contradicts NCCN guidance, you have some cancer care affordability summits 2026 homework to do before changing your treatment protocols.
Key Theme 1: ASCO Immunotherapy and Beyond
When searching the program, you will see a massive volume of sessions dedicated to ASCO immunotherapy. This isn't just about checkpoint inhibitors anymore. The focus has shifted toward:
- Bispecific T-cell engagers: Moving beyond traditional PD-1/PD-L1 monotherapy. Combination strategies: How do we mitigate toxicities while maximizing durable responses? Adjuvant and Neoadjuvant applications: The shift of immunotherapy into earlier disease stages.
My advice: Avoid the sessions that just list "improved response rates." Look for the sessions that focus on long-term toxicity management. If you don't know how to handle the immune-related adverse events (irAEs) that show up six months after the trial concludes, that data isn't useful for your Monday morning clinic.
Key Theme 2: Precision Oncology Biomarkers
You ever wonder why we are well past the "one-size-fits-all" era. Precision oncology biomarkers are the backbone of modern practice. ASCO covers a broad spectrum here, ranging from liquid biopsies and ctDNA monitoring to the identification of rare mutations in solid tumors.
What to Look for in Biomarker Sessions:
Utility over novelty: Does the biomarker actually predict response to a specific drug, or is it just a prognostic marker? Access and Testing: If you see a biomarker identified, is there a companion diagnostic that is FDA-approved and covered by insurance? Clinical trial design: Are the patients in the trial representative of your patient population?Key Theme 3: Clinical Trials Oncology and Translational Research
Navigating clinical trials oncology sessions can be overwhelming. As an editor, I suggest categorizing your attendance by trial phase. Don't waste your time in a Phase I session if you are looking for immediate practice-changing data for your community clinic. Save that for the Phase III results.
Trial Phase What to Expect Clinical Takeaway Phase I Dose-finding, safety signals Understanding mechanism, not yet practice change. Phase II Preliminary efficacy Potential signals for future treatment options. Phase III Comparative efficacy, OS/PFS benefits Direct impact on NCCN guidelines and Monday workflows.Key Theme 4: AI and Computational Oncology
I know, I know—everyone is talking about AI. Most of the agenda items related to AI and computational oncology are, frankly, vague. I cringe when I see descriptions that claim an algorithm will "revolutionize patient care" without explaining the data set or the clinical validation process. When attending these sessions, keep your skepticism high. Ask the speaker: "How was this model validated, and what is the error rate in a real-world clinical setting?"
How to Organize Your ASCO Schedule
I keep a running spreadsheet for every conference I manage. I recommend you do the same. Don't just bookmark sessions in the app; build a simple table:
- Date/Time: When is it? Session Type: Is it a clinical trial update, a poster session, or a guideline review? Clinical Relevance: How does this apply to my specific patient panel? Action Item: What protocol do I need to review if this data is confirmed?
The "Monday Morning" Reality Check
Before you commit to a long block of sessions, ask yourself if the speaker is overclaiming. If an abstract from a single, small study claims to be the "new standard of care," treat it with caution. Oncology is a science of cumulative evidence, not singular miracles. True progress happens in the iterative, often tedious work of refining trial designs and verifying biomarkers.
If you find this guide helpful for your upcoming meeting, please share it with your oncology team so you can divide and conquer the agenda.
Share on Facebook | Share on X (Twitter)
Final tip: If you attend a session and leave feeling more confused about your Monday morning clinical workflow than when you entered, the speaker didn't do their job. Don't feel guilty about walking out to catch a different session. Your time is your most valuable asset.